Structure Therapeutics (NASDAQ:GPCR) Posts Quarterly Earnings Results, Beats Estimates By $999.35 EPS

Structure Therapeutics (NASDAQ:GPCR) posted its quarterly earnings data on Thursday. The company reported $999.00 EPS for the quarter, beating the consensus estimate of ($0.35) by $999.35, reports.

Structure Therapeutics Stock Performance

NASDAQ GPCR traded down $1.78 during trading hours on Thursday, hitting $64.75. The company had a trading volume of 939,537 shares, compared to its average volume of 880,593. The business has a 50 day moving average of $75.45 and a 200-day moving average of $46.22. The company has a market cap of $4.57 billion, a PE ratio of -53.07 and a beta of -2.06. Structure Therapeutics has a 1-year low of $13.22 and a 1-year high of $94.90.

Wall Street Analyst Weigh In

GPCR has been the topic of a number of research reports. Stifel Nicolaus increased their target price on shares of Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. BMO Capital Markets reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, January 6th. Morgan Stanley upped their price target on Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Finally, JPMorgan Chase & Co. lifted their price objective on Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $106.20.

Institutional Trading of Structure Therapeutics

A number of large investors have recently made changes to their positions in GPCR. HighTower Advisors LLC increased its stake in Structure Therapeutics by 3.6% in the 4th quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock valued at $648,000 after buying an additional 320 shares during the period. State of Wyoming boosted its holdings in shares of Structure Therapeutics by 29.7% in the fourth quarter. State of Wyoming now owns 1,761 shares of the company’s stock valued at $122,000 after acquiring an additional 403 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Structure Therapeutics by 14.5% during the third quarter. Envestnet Asset Management Inc. now owns 12,220 shares of the company’s stock worth $342,000 after acquiring an additional 1,544 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Structure Therapeutics during the fourth quarter worth about $127,000. Finally, State Street Corp raised its holdings in Structure Therapeutics by 4.8% during the fourth quarter. State Street Corp now owns 48,224 shares of the company’s stock worth $3,354,000 after purchasing an additional 2,207 shares in the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.